Abstract
Quantitative structure activity relationships were developed for seventeen propenone derivatives reported in the literature that act as dual COX and 5-LOX inhibitors. Predominantly spatial, thermodynamic, topological, and electronic descriptors appear in the models. Docking between these compounds and COX-1, COX-2 and 5-LOX enzymes was also performed and mathematical relationships were developed between the binding energy and activity.
Letters in Organic Chemistry
Title: QSAR and Docking Studies on Propenone Derivatives as Dual COX and 5- LOX Inhibitors
Volume: 5 Issue: 7
Author(s): Ponnurengam M. Sivakumar, Sethu K. Geetha Babu, Vaibhav Sharma and Mukesh Doble
Affiliation:
Keywords: Propenone, NSAID, QSAR, COX -1, COX-2, 5-LOX
Abstract: Quantitative structure activity relationships were developed for seventeen propenone derivatives reported in the literature that act as dual COX and 5-LOX inhibitors. Predominantly spatial, thermodynamic, topological, and electronic descriptors appear in the models. Docking between these compounds and COX-1, COX-2 and 5-LOX enzymes was also performed and mathematical relationships were developed between the binding energy and activity.
Export Options
About this article
Cite this article as:
Sivakumar M. Ponnurengam, Geetha Babu K. Sethu, Sharma Vaibhav and Doble Mukesh, QSAR and Docking Studies on Propenone Derivatives as Dual COX and 5- LOX Inhibitors, Letters in Organic Chemistry 2008; 5 (7) . https://dx.doi.org/10.2174/157017808785982194
DOI https://dx.doi.org/10.2174/157017808785982194 |
Print ISSN 1570-1786 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6255 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Epigenomic-Basis of Preemptive Medicine for Neurodevelopmental Disorders
Current Genomics Pharmacological Management of Psychosis in Parkinson Disease: A Review
Current Drug Therapy Nucleus Accumbens Dopamine and the Forebrain Circuitry Involved in Behavioral Activation and Effort-Related Decision Making: Implications for Understanding Anergia and Psychomotor Slowing in Depression
Current Psychiatry Reviews Policy and Adolescent Tobacco Use Prevention
Adolescent Psychiatry Neurodegeneration in Diabetic Retina and Its Potential Drug Targets
Current Neuropharmacology Editorial: Pharmacotherapy of Alcohol Dependence: Past, Present and Future Research
Current Pharmaceutical Design Triple Reuptake Inhibitors: The Next Generation of Antidepressants
Current Neuropharmacology GPU Acceleration of an Entropy-Based Model to Quantify Epistatic Interactions Between SNPs
Current Bioinformatics Bridging Neurocognitive Aging and Disease Modification: Targeting Functional Mechanisms of Memory Impairment
Current Alzheimer Research Vitamin D Combined with Resveratrol Prevents Cognitive Decline in SAMP8 Mice
Current Alzheimer Research Review of Patents on Microneedle Applicators
Recent Patents on Drug Delivery & Formulation Novel Therapeutic Strategy in the Management of COPD: A Systems Medicine Approach
Current Medicinal Chemistry B-Cell Based Gene Therapy for Autoimmune Diseases
Infectious Disorders - Drug Targets Pharmacological Properties of Physical Exercise in The Elderly
Current Pharmaceutical Design Commentary
CNS & Neurological Disorders - Drug Targets Vitamin D and Cardiovascular Disease: A Novel Agent for Reducing Cardiovascular Risk?
Current Vascular Pharmacology Effects of Nicotine During Pregnancy: Human and Experimental Evidence
Current Neuropharmacology The Interaction of Depression and Diabetes: A Review
Current Diabetes Reviews Immigration, Social Environment and Onset of Psychotic Disorders
Current Pharmaceutical Design Risk Communication of Vaccines: Challenges in the Post-Trust Environment
Current Drug Safety